Quantcast

Latest Temozolomide Stories

2014-12-02 08:32:26

PORTLAND, Oregon, December 2, 2014 /PRNewswire/ -- GBI Research, the leading business intelligence provider, has released its latest research, "Glioblastoma Multiforme

2014-12-02 08:31:14

Based on the results of the trial's pre-specified interim analysis all control patients in the EF-14 phase III trial will be offered the opportunity to cross over to receive Tumor Treating Fields

2014-12-01 08:30:21

Planned interim analysis demonstrates the EF-14 Phase III trial met its endpoints of progression-free survival and overall survival ST. HELIER, Jersey, Dec.

2014-11-17 08:30:19

Data Presented at the 19th Annual Society for Neuro-Oncology Meeting Demonstrate VAL-083 Superiority to Temozolomide in Key Preclinical Models VANCOUVER, British Columbia, MENLO PARK, Calif.,

2014-11-15 12:21:23

Data presented today as a late-breaking abstract at the Society for Neuro-Oncology 2014 Annual Meeting in Miami demonstrated the EF-14 trial met its primary endpoint of progression-free survival and

2014-11-14 16:25:22

- Data include results from a Phase 1 study of ABT-414 as monotherapy and in combination with radiation and/or chemotherapy in patients with newly diagnosed and recurrent/unresectable glioblastoma

2014-11-14 12:25:46

VAL-083 Anti-tumor Activity Is Consistently Superior to Temozolomide in Preclinical Models of Glioblastoma VANCOUVER, British Columbia, MENLO PARK, Calif., and MIAMI, Nov.

2014-11-14 08:27:59

Continued Positive Trends in Overall Survival and Progression-Free Survival; LOS ANGELES, Nov. 14, 2014 /PRNewswire/ -- ImmunoCellular Therapeutics, Ltd.


Word of the Day
shavie
  • A trick or prank.
The word 'shavie' is related to 'shave'.